How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of COVID-19 in individuals 5 years of age and older — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of COVID-19 in individuals 5 years of age and older (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of COVID-19 in individuals 5 years of age and older, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	vaccine	SARS-CoV-2 virus	2021-08-23
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg	bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg	Pfizer	mRNA vaccine	Spike protein
Tozinameran 5 to 11 Years of age	tozinameran-5-to-11-years-of-age	Pfizer	vaccine	SARS-CoV-2 virus
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	Monoclonal antibody	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	mRNA vaccine	SARS-CoV-2 spike protein
Combination (Bivalent) BNT162b2 and BNT162b2 OMI	combination-bivalent-bnt162b2-and-bnt162b2-omi	Pfizer	vaccine	SARS-CoV-2 virus
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)	bnt162b7-bivalent-original-omi-ba-4-ba-5	Pfizer	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 vaccine	BNT162b2 vaccine	Vaxxinity, Inc.	Not specified	Not specified
Investigational COVID-19 Vaccine	Investigational COVID-19 Vaccine	BioNTech	Not specified	Not specified
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	vaccine	SARS-CoV-2 spike protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 12 drugs in Prevention of COVID-19 in individuals 5 years of age and older
Pfizer Inc. · 2 drugs in Prevention of COVID-19 in individuals 5 years of age and older
BioNTech · 1 drug in Prevention of COVID-19 in individuals 5 years of age and older
Vaxxinity, Inc. · 1 drug in Prevention of COVID-19 in individuals 5 years of age and older

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of COVID-19 in individuals 5 years of age and older:

Cite this brief

Drug Landscape (2026). Prevention of COVID-19 in individuals 5 years of age and older — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older. Accessed 2026-06-10.

Prevention of COVID-19 in individuals 5 years of age and older full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing